ponsegromab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Weight LossCachexiaNon-Small Cell Lung Cancer (NSCLC)

105 competitors in Weight Loss

#DrugCompanyPhaseTrials

1

Megace

Bristol-Myers Squibb

Phase 3

102

Byetta

AstraZeneca

Phase 3

33

Mounjaro

Eli Lilly

Phase 3

14

Revia

Teva

Phase 3

15

Glucophage

EMD Serono

Phase 3

86

Meridia

AAbbott

Phase 3

77

Botox

RRevance Therapeutics, Inc.

Phase 3

18

Rimonabant

Sanofi

Phase 3

19

Cagrilintide

Novo Nordisk

Phase 3

110

Byetta

Bristol-Myers Squibb

Phase 3

1Show 39 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cachexia2 trials

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

Completed·Pfizer·Phase 2·NCT05546476·187 enrolled

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·Pfizer·Preclinical·NCT06989437·982 enrolled

Adult1 trial

A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults

Completed·Pfizer·Phase 1·NCT05685264·18 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

AN INTERVENTIONAL, PHASE 1B, DOUBLE-BLIND, RANDOMIZED, SPONSOR-OPEN, 2-ARM STUDY TO INVESTIGATE THE EFFECT OF PONSEGROMAB ON SKELETAL MUSCLE MASS AND PHYSICAL FUNCTION IN ADULT PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER ASSOCIATED CACHEXIA

Not yet recruiting·Pfizer·Phase 1·NCT07663630·80 enrolled

Details

Drug Info

Related News